Sie sind auf Seite 1von 4

Approved by

The Rector of State Educational Institution of Higher Professional Education


Nizhny Novgorod State Medicine Acadey
Professor !"E" Sha#hov (Signature)
Septeber $%& '$$(
(Seal: State Educational Institution of Higher Professional Education
Nizhny Novgorod State Medicine Academy)
Minutes
of Clinical Tests to Study
the Efficiency of Treatment of Pelvic Inflammatory Diseases (virulent and chronic forms)
using DETA-A device in gynecology
'$$(
Test !asis" Post)Approval *linical Testing Agreeent dated Noveber $+& '$$,"
Test aim" to deterine the efficiency of therapy of patients having pelvic inflaatory diseases
associated -ith chlaydia& ycoplasa& ureaplasa& cytoegala virus& herpes infection& HP.
infection& using /ETA)AR device"
Ty#e of testing" open& non)rando& coparative"
Test tas$"
0" to deterine the clinical efficiency of traditional antibacterial and antiviral
therapy for patients having pelvic inflaatory diseases associated -ith chlaydia&
ycoplasa& ureaplasa& cytoegala virus& herpes infection& HP. infection"
'" to deterine the clinical efficiency of /ETA)AR therapy for patients having
pelvic inflaatory diseases associated -ith chlaydia& ycoplasa& ureaplasa&
cytoegala virus& herpes infection& HP. infection as the treatent ethod additional to
traditional antibacterial and antiviral therapy"
1" to deterine the clinical efficiency of /ETA)AR therapy for patients having
pelvic inflaatory diseases associated -ith chlaydia& ycoplasa& ureaplasa&
cytoegala virus& herpes infection& HP. infection as the only treatent ethod"
%" To assess the safety of /ETA)AR application -hen treating the above entioned
diseases"
Plan of testing"
2oen of reproductive age 30,)%' years old4 having out)patient treatent in the aternity
-elfare clinic No" 0$ of Maternity Hospital No" %& a unicipal prevention and treatent facility
-ere included into the testing"
Patient -ere selected in accordance -ith the specified inclusion criteria"
Inclusion criteria" Patients having pelvic inflaatory diseases 3virulent and chronic fors4
associated -ith chlaydia& ycoplasa& ureaplasa& cytoegala virus& herpes infection& HP.
infection& evidenced by iune and enzye blood analysis and polyerase chain reaction of
s-abs& and having chronic and virulent inflaatory diseases of feale genitals& participated in
the tests"
Tests and treatent -ere carried out on the basis of infored voluntary consent of the patient
according to the 5rder No" 061 3Industry)specific Standard 35ST4 (07$$"0%"$$$0)'$$'4 of the
Ministry of Health of the Russian 8ederation" The tests have been agreed -ith the local ethics
coittee State Health *are Institution of Nizhny Novgorod Region N"A" Seash#o *linical
Hospital"
Time and #lace of the tests" aternity -elfare clinic No" 0$ of Maternity Hospital No" %& a
unicipal prevention and treatent facility in Nizhny Novgorod fro Noveber $+& '$$,& till
/eceber $0& '$$("
e#resented for the tests"
0" /ETA)AR device anufactured by 555 E9IS Research and /evelopent Enterprise
3Mosco-4& 1 ites& soft-are of the device provides antiparasitic electroagnetic -ave
therapy"
'" /ETA)AR devices are authorized for application in edicine 3Registration certificate of
the 8ederal Service on Surveillance in Healthcare and Social /evelopent of Russian
8ederation No" 8S $'' a 0+0$:%6'7)$6 of /eceber ''& '$004"
1" /ETA)AR Manual"
%" Methodological recoendations for application of /ETA)AR"
/iagnosis and treatent ethods are covered by patents No" '$$$00%7+, dated March '$&
'$$1& used by 555 E9IS Research and /evelopent Enterprise on the legal basis"
Test results"
The research of clinical efficiency of different -ays to treat pelvic inflaatory diseases caused
by chlaydia& ycoplasa& ureaplasa& cytoegala virus& herpes infection& HP. infection
conducted aong %7 patients 3-oen4 being fro 0, to %' years old 3average age is '(&1 ;0&0
years4"
The diagnosis of diseases is ade clinically and evidenced by iune and enzye blood
analysis and detection of /NA agents paragraphs applying the ethod of polyerase chain
reactions"
The main grou# -as divided into ' subgroups<
the 0
st
3N04 group = cobination of drug and bioresonance therapy" The '
nd
3N'4 group had
/ETA)AR therapy only"
The control group 3N14 3drug therapy only4 consisted of 77 persons 3-oen4 being fro 0, to
%' years old 3average age is '6"1 > 0"' years4"
The study groups -ere of siilar age& nosological entities and severity of the underlying disease"
Treatent ethod" /ETA device -as prepared to the treatent in accordance -ith the /ETA
/evice Manual" The device -as s-itched on and off in accordance -ith the instructions of the
Manual" /uring the session the device -as located in the pro?ection of the hotbed of disease of
the patient" The period of session depended on the individual set of progras& average %$)6$
inutes" All patients of the ain group had 1 sessions of bioresonance therapy every second day
and 1 sessions of deto@ification bioresonance therapy"
The efficiency of applied ethods is assessed through clinical e@aination once per t-o days&
including assessent of the general state of health& theroetry& special gynecological
e@aination 3before and after the full course of therapy4& at the beginning and at the end of
therapy< ultrasound investigation of pelvic organs& coplete blood count deterining ESR
leu#ogra& leu#ocyte inde@ of into@ication& vagina icrobiocenosis before and after light
icroscopy treatent and bacteriological study"
*linical onitoring of patients treated by /ETA)AR device as the sole therapy and cobined
-ith drug treatent& revealed a ore pronounced positive effect coparing to the control group
receiving standard antibacterial and antiviral therapy" The efficiency of treatent -as e@pressed
by noralization of teperature& *oplete !lood *ount indices& local status" Eliination of
pain 3constant dull aching lo-er abdoinal pain4 aong the patients in the ain group too#
place on the second day& that is 1 ties faster than in the control group"
*linical characteristics of the study groups and the influence of various treatents of pelvic
inflaatory diseases are represented in Table 0"
Table 0"
/iagnosis
Nuber of
patients
Average duration of
treatent by
cobining drug and
bioresonance
therapy
Average duration of
/ETA)AR therapy
only"
Average duration of
traditional drug
therapy
N0 N' N1
*laidiosis 6 ' 0$ 0'&';0&% 1;$ 0%&71;0&+
Mycoplasosis 1 ' ( +&'1;0&0 1;$ ,;0&1
Arealasosis 6 ' 0$ ,&(1;$&( 1;$ (&11;0&0
*ytoegala
virus
6 1 , 0$&+1;0&' 1;$ 0'&'1;0&7
HP. infection 7 1 0$ 0%&%1;0&1 1;$ 07&(1;0&1
Herpes
infection
% 1 , '0&1;'&+ 1;$ '%&71;1&$
Tolerance% It should be noted that /ETA)AR is convenient& and the therapy is -ell)tolerated&
there is lac# of general and local adverse reactions in the treatent of pelvic inflaatory
diseases associated -ith chlaydia& ycoplasa& ureaplasa& cytoegala virus& herpes
infection& HP. infection"
The therapy did not have negative ipact on the concoitant soatic pathology of patients"
Moreover& the use of regenerative freBuency provided in antiparasitic progras of /ETA)AR
device contributes to ore rapid restoration of anatoy and function of daaged organs"
Conclusion%
0" Insufficient clinical efficiency of traditional antibacterial and antiviral therapy for
patients having pelvic inflaatory diseases associated -ith chlaydia& ycoplasa&
ureaplasa& cytoegala virus& herpes infection& HP. infection is detected 36$)67C4"
'" Pronounced clinical efficiency of /ETA)AR therapy together -ith traditional
drug therapy for patients having pelvic inflaatory diseases associated -ith chlaydia&
ycoplasa& ureaplasa& cytoegala virus& herpes infection& HP. infection is detected
3,+)('C4& as -ell as the only treatent ethod 3,7C4"
1" There is no contraindication to the use of /ETA)AR device aong the patients
having pelvic inflaatory diseases associated -ith chlaydia& ycoplasa&
ureaplasa& cytoegala virus& herpes infection& HP. infection"
%" /ETA)AR device ay be used during the hospital and out)patient treatent and
at hoe"
Supervisor<
/octor of Medicine& Professor
*hair of the 5bstetrics and Denecology Subdepartent of
(Signature)
Advanced Training /epartent of State Educational
Institution of Higher Professional Education Nizhny
Novgorod State Medicine Acadey
9"." !orov#ova
E@ecutive in charge<
*andidate of Medicine& Assistant of 5bstetrics and
Denecology Subdepartent of Advanced Training
/epartent of State Educational Institution of Higher
Professional Education Nizhny Novgorod State Medicine
Acadey
(Signature)
/"." Pershin
Head doctor of Maternity Hospital No" %& a unicipal
prevention and treatent facility in Nizhny Novgorod
(Signature)
A"." Egorov
(Seal: Maternity Hosital No! "# a municial revention and treatment facility# $enins%y
&istrict# Nizhny Novgorod)